» Articles » PMID: 29628281

EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2018 Apr 10
PMID 29628281
Citations 3548
Affiliations
Soon will be listed here.
Citing Articles

Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria.

Kim J, Kim J, Ko E, Kim J, Im B, Kim G Cancers (Basel). 2025; 17(5).

PMID: 40075741 PMC: 11898427. DOI: 10.3390/cancers17050894.


Integrating CT Radiomics and Clinical Features to Optimize TACE Technique Decision-Making in Hepatocellular Carcinoma.

Masthoff M, Irle M, Kaldewey D, Rennebaum F, Morgul H, Pohler G Cancers (Basel). 2025; 17(5).

PMID: 40075740 PMC: 11899091. DOI: 10.3390/cancers17050893.


Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer.

Samanta T, Park J, Kaipparettu B Cancers (Basel). 2025; 17(5).

PMID: 40075691 PMC: 11898429. DOI: 10.3390/cancers17050844.


Gamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy.

Zhou P, Huang R, Wang H, Yang J, Peng J, Fu Z World J Gastrointest Surg. 2025; 17(2):98578.

PMID: 40061977 PMC: 11886001. DOI: 10.4240/wjgs.v17.i2.98578.


Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer.

Wei X, Cao W, Wang S, Zhang Y, Gao Z, Wang S Int J Nanomedicine. 2025; 20:2623-2643.

PMID: 40061885 PMC: 11887507. DOI: 10.2147/IJN.S509409.